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Cadmium is a widely distributed, toxic trace
metal. Cadmium poisoning causes damage
to major organ systems, and in humans this
leads to Itai-Itai disease (1,4. This nonessen-
tial transition metal is also carcinogenic
(3-5) and is deleterious to the reproductive
process, causing retardation ofgrowth, steril-
ity, teratogenic, and embryotoxic effects
(6-8). In rodents, spermatogenesis has long
been known to be highly susceptible to cad-
mium. In sensitive strains ofmice, the testes
undergo necrosis after exposure to cadmium
(9,10). Likewise, injection of pregnant
female mice with a sublethal dose ofcadmi-
um on the day of blastocyst implantation
(day 4) significandy reduces pregnancy rate
by midgestation (11). Cadmium exerts
embryotoxic effects on preimplantation
embryos in vitro (12,13), and these effects
are particularly dependent on the stage of
embryonic development, with the blastocyst
being the most sensitive to cadmium toxicity
(11,14). However, cadmium also exerts toxic
effects on the female reproductive tract and
can delay the onset of implantation (11).
After implantation, the deciduum, placenta,
and visceral yolk sac may serve to protect the
embryo by restricting the passage of cadmi-
um from the mother, but exposure to cadmi-
um during the organogenic period can
induce limb bud and craniofacial defects
(6,7). Mechanisms that may protect against
the reproductive toxicity of cadmium are
largely unknown.
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Metallothioneins (MT) are a family of
cysteine-rich cadmium-binding proteins
(15) whose genes are transcriptionally acti-
vated by cadmium (16). Because MTs have
been shown to protect against cadmium
toxicity in cultured cells (17,18) and in
mice (19-21) they are prime candidates for
protecting against toxic effects ofcadmium
on reproductive processes.
Several strains of mice that overexpress
MT have been created using a minimally
mutated MT-I (MT-Ij gene under the
control of 1.8-kb of the mouse MT-I pro-
moter and flanked by the MT-I/MT-I]
locus control regions (LCR) (22). In these
mice, the MT-I*transgene is expressed in a
copy-number-dependent, integration-site-
independent manner, and developmental
expression appears to mimic the endoge
nous gene. We examined one of these
transgenic mouse strains and reported tha
MT is overexpressed in most major organ
(23). In this study we documented th(
level ofexpression and tissue-specific distri
bution of MT in reproductive organ
(uterus and testes) of male and femalb
transgenic and control mice from thi
strain and evaluated the role ofMT in pro
tection against cadmium-induced testiculai
damage and early pregnancy failure.
Methods
Animals. All experiments involving ani
mals were conducted in accordance witl
National Institutes of Health standards for
the care and use of experimental animals.
The transgenic mice used in these studies
were derived from heterozygous males that
carry 56 copies ofminimally mutated MT-I
(MT-Ij gene on the B6/SJL F1 background
(22). These mice were outbred to CD-1
females (Charles River Breeding
Laboratories, Raleigh, North Carolina), and
the heterozygous male offspring were select-
ed. These heterozygous males were bred
with CD-1 females, and experiments were
performed using the transgenic and non-
transgenic (control) littermates from this
breeding. We identified transgenic and con-
trol mice by DNA slot blot analysis. For
experiments involving pregnant animals,
virgin females of the indicated strain
(48-68 days old) were mated with males of
the indicated strain, and the morning a
vaginal plug was detected was defined as
f day 1 ofpregnancy.
s Cadmium injection. CdCl2 (Sigma
Chemical Co., St. Louis, Missouri) was dis-
e solved in acidified normal saline and
I administered in a single 100-pl subcuta-
I neous injection. Dosages of cadmium
r ranged from 7.5 to 45 pmol/kg body
weight. To determine the effect of cadmi-
um on pregnancy, we injected cadmium on
s the morning ofday 4 and assessed pregnan-
y cy success on day 14 as described (11). The
e effect of cadmium on the testes was deter-
- mined by histological examination 24 and
I 48 hr after cadmium injection.
e MTdetermination. MT was determined
a by the cadmium-hemoglobin exchange
assay as described (24). For convenience,
LI tissue samples were frozen in liquid nitro-
gen and stored at -700C before analysis.
e
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Isolation ofRNA and Northern blot
hybridization. Tissues were frozen in liquid
nitrogen and stored at -700C before RNA
extraction. RNA was prepared by an initial
guanidine thiocyanate (GTC)/phenol/chlo-
roform extraction as described (25), fol-
lowed by sodium dodecyl sulfate
(SDS)/phenol/chloroform extractions
(26,27). Poly A+ RNA was isolated as
described by Aviv and Leder (28), using
total RNA and oligo(dT) cellulose
(Collaborative Biochemicals, Bedford,
Massachusetts; 20 mg total RNA/0.5 g cel-
lulose).
RNAwas size fractionated by formalde-
hyde-agarose gel electrophoresis and
Northern blotted to nylon membranes
(29). Northern blots were prehybridized,
hybridized with a mouse MT-I 32P-labeled
cRNA probe (specific activity = 2 x 109
dpm/pg), and washed (26,29,30). Hybrids
were detected by autoradiography at -700C
with intensifying screens. In all experi-
ments, we stained duplicate gels with acri-
dine orange to verify integrity and equal
loading ofRNA.
Competitive reverse transcniptase-PCR
analysis ofMT-I and MT-I* mRNAs.
Competitive reverse transcriptase-poly-
merase chain reaction (RT-PCR) was per-
formed, under reaction conditions essen-
tially as described (31), to differentiate
between MT-I* and endogenous MT-I
mRNAs. Oligonucleotide primers specific
for MT-I were designed based on the
sequence of the mouse MT-I cDNA that
flanks the MT-I*mutation (32):
sense strand
5' CACCACGACTTCAACGTCCTG 3'
antisense strand
5' TCTTGCAGGCGCAGGAGCTG 3'
These primers correspond to nucleotides
3-23 in the 5' untranslated region (exon 1)
and to nucleotides 604-623 (exon 2) ofthe
mouse MT-Igene, respectively. Total RNA
(25 pg) was reverse transcribed with recom-
binant mouse murine leukemia virus
reverse transcriptase (Gibco-BRL,
Gaithersburg, Maryland) using the anti-
sense oligo as a primer. One-fourth ofthe
RT reaction mixture was amplified by PCR
for 20 cycles in a reaction containing 0.2
pM each unlabeled MT-I primer, 1 x 107
cpm of32P-5'-end labeled antisense MT-I
primer (5-10 x 106 dpm/pmol), and 1
unit of Taq polymerase (Perkin-Elmer
Cetus, Norwalk, Connecticut). Cycle para-
meters were as follows: cycle 1: 940C for 4
min, primer annealing at 550C for 2 min
and primer extension 720C for 2 min;
cycles 2-20: 940C for 30 sec, 550C for 2
min, and 72°C for 2 min. RT-PCR prod-
ucts were purified using magic PCR prep
columns (Promega Biotech, Madison,
Wisconsin) and 1 x 105 cpm was digested
with excess restriction enzyme (Bgl II
and/or EcoRl). EcoRV will cleave the MT-
I* product, whereas Bgl II cleaves the
endogenous MT-I gene product (22).
Restriction fragments were separated by
12% nondenaturing polyacrylamide gel
electrophoresis. After fixation in 10%
acetic acid for 10 min, the gel was dried
and exposed to Kodak XAR-5 film at
-700C for a fewhours.
Solution hybridization. Oligo-
nucleotide excess solution hybridization
was used to quantitate MT-I mRNA levels
as described (33). Total RNA or poly A'
RNA (0-30 pg) plus carrier E. coli rRNA
(20-50 pg; Boehringer Mannheim,
Indianapolis, Indiana) were mixed and
hybridized with 10 fmol of32P-end-labeled
antisense oligonucleotide complementary
to the 3' untranslated region ofMT-I (34)
as described previously (30,33). The
oligonucleotide was end-labeled with T4
polynucleotide kinase according to the
manufacturer's suggestions (New England
Biolabs, Inc., Beverly, Massachusetts) and
had a specific activity of 5-10 x 106
cpm/pmol. After hybridization, SI nucle-
ase resistant nucleic acids were precipitated
with 20% trichloroacetic acid and collected
on glass fiber filters (Whatman GF/C;
Fisher Scientific, Pittsburgh, Pennsylvania)
and the radioactivity was measured by liq-
uid scintillation counting. Samples were in
duplicate. Each set of hybridization reac-
tions also included a standard curve gener-
ated using known amounts ofsense-strand
RNA which was transcribed in vitro from
the MT-I cDNAclone (33).
MT antibodies. A rabbit polyclonal
antisera against a synthetic peptide corre-
sponding to the amino-terminal 15 amino
acids of mouse MT-I (NacMDPNASA
STGGSATCamide) (32) was prepared
commercially by Immuno-Dynamics (La
Jolla, California). Fine epitope mapping of
rat MT-II suggested that the acetylated
amino-terminal pentapeptide is the primary
antigenic determinant and that the acetate
group on the amino-terminal methionine is
important for antigenicity (35). Therefore,
the peptide was acetylated on the amino-
terminal methionine after synthesis and the
C-terminal cysteine carboxyl group was
converted to an.amide. Cysteine residues
corresponding to amino acids 5, 7, and 13
were substituted with alanine. For injection,
this peptide was conjugated to keyhole
limpet hemocyanin through the C-terminal
cysteinesulfhydryl group.
Immunohistochemistny and histology.
Immunolocalization of MT-I was per-
formed essentially as described (27,36-38).
Briefly, uteri were excised, cleaned of fat,
and either fixed intact in Bouin's solution or
implantation sites were grossly dissected
from interimplantation regions and then
fixed in Bouin's. Testes were removed from
mature males (>68 days old) after perfusion
fixation with Bouin's and cut into small
pieces which were further fixed in Bouin's.
Fixed tissues were dehydrated and embed-
ded forparaffin sections. Paraffin sections (7
pm) were incubated in 10% normal goat
serum for 10 min before incubation with
primary antibody (1:500 dilution) for
16-20 hr at 4°C. For uteri, we used a kit
for the anti-rabbit primaryantibody (Zymed
Laboratories, San Francisco, California) for
immunostaining. This kit used a biotinylat-
ed secondaryantibody, ahorseradish peroxi-
dase-streptavidin conjugate, and a substrate
chromogen mixture. After incubation in sec-
ondary antibody, we blocked endogenous
peroxidase by incubation in 0.23% periodic
acid in phosphate-buffered saline for 45 sec
(39). For testis, we used a kit containing a
biotinylated secondary antibody, an alkaline
phosphatase-streptavidin conjugate, and an
AP-red substrate chromogen mixture for
immunostaining. After color development,
sections were counterstained lightly with
hematoxylin, mounted, andexamined under
bright field. Red deposits indicated sites of
immunostaining. No specific staining was
detected in control sections incubated with-
out primary antibody or with nonimmune
serum. Furthermore, in all cases specific
stainingwas greatly reduced oreliminated in
sections in which the primary antibody was
neutralized with a 200-fold excess of MT
peptide. For histological analysis of the
testes, we used the same fixation, embed-
ding, and sectioning procedures, and sec-
tions were stainedwith eosin.
Results
MT-I mRNALevels
To determine whether MT transgenes are
overexpressed in the testes and peri-implan-
tation uterus of transgenic animals, total
RNA was prepared from these tissues and
MT-I mRNA levels were quantitated by
solution hybridization. This assayemployed
an oligonucleotide that detected both
endogenous MT-I and transgene-derived
MT-I* transcripts. MT-I mRNAlevels were
elevated 8.3-fold in total RNA from the
testes of transgenic compared with control
nontransgenic littermates (Fig. 1A). In the
uterus, at sites of embryo implantation,
MT-I mRNA levels were elevated 20.2-fold
on day 6 and 8.6-fold on day 8 compared
to levels in control mice. During this peri-
od, days 6-8, there is massive growth ofthe
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deciduum, which surrounds the embryo
and actively expresses the entire MTgene
locus (33,40). Northern analysis showed
that MT-I mRNA levels in transgenic mice
are highest in the implantation sites/decidu-
um compared to the interimplantation
regions of the uterus (Fig. 1B). Solution
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hybridization and Northern analysis both between days 6 and 8, as previously shown
show a developmental increase in MT-I in CD-1 mice (40).
mRNA levels in the deciduum of control We used competitive RT-PCR to evalu-
(11.2-fold) and transgenic (4.8-fold) mice ate the relative expression of MT-I* trans-
genes and the endogenous MT-Igene in the
Testes testes and peri-implantation uterus oftrans-
/ I +1- genic mice. Transcripts from the MT-I*
gene contains an EcoRV site derived by
modification of the BgIII site at +62 in the
5'-untranslated region (24. RT-PCR across
this region using oligonucleotides comple-
mentary to both transcripts, followed by
cleavage of the RT-PCR product with
EcoRV and/or BgAI, differentiates products
derived from the MT-I* transgene and the
4 4.p . endogenous MT-Igene, respectively. Results
4 twt 4 <>;> ofthis analysis revealed that RT-PCR prod-
ucts from MT-I* mRNA represent the
majority (>90%) ofthe MT-I mRNA in the
testes and peri-implantation uterus from
D6Deciduum transgenic mice (Fig. 2). As expected, EcoRVdoes not cut RT-PCRproducts from
.-. l I. -control mice. These RT-PCR products do
not represent PCRofDNAbecause they are
dependent on reverse transcription, and
PCR of genomic sequences would yield a
larger product due to the inclusion of
intronic sequences. The nature of the larger
PCR product that was not cut with EcoRV
or BgIII was not investigated, but probably
4^ ^ 4 bg represents heteroduplexes (2Z.
Restriction Enzymes
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Figure 1. MT-I mRNA levels in the testes and peri-
implantation uterus of transgenic and control
mice. (A) Total MT-I (MT-I plus MT-I*) mRNA was
quantitated by solution hybridization using an
excess of an oligonucleotide complementary to
MT-I mRNA. Sense-strand MT-I RNA was used to
generate a standard curve for quantitation of MT-
I mRNA levels. Data are expressed as means ±
SDs, n = 6). For each tissue, the transgenic mRNA
level was significantly different from control (p <
0.001, Student's t-test). Testis RNA was obtained
from four to six animals for each group. Sites of
blastocyst implantation site were dissected and
pooled from the uteri of pregnant mice (n = 4) on
days 6 and 8 of pregnancy. Implantation sites on
day 8 were dissected free ofthe myometrium. (B)
The top panel is a Northern blot of MT-I mRNA in
total RNA (2 pg) from implantation sites (IS) or
interimplantation sites (IIS) isolated from the uteri
of pregnant mice on days 6 or 8 ofgestation/preg-
nancy. RNAs from control (-) and transgenic (+)
mice are compared. The bottom panel is an acri-
dine orange-stained duplicate gel which demon-
strates equal loading of 28s and 18s ribosomal
RNAs.
DBDeciduum
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Figure 2. Competitive reverse transcriptase-poly-
merase chain reaction (RT-PCR) analysis ofthe rel-
ative abundance of MT-I and MT-I* mRNAs in the
testes and peri-implantation uterus of transgenic
and control mice. Total RNA from control (-I-) and
transgenic (+/-) tissues was subjected to competi-
tive RT-PCR using oligonucleotides that flank the
MT-I* mutation and that are complementary to
MT-I and MT-I* mRNAs. The MT-I mRNA RT-PCR
product is cut by Bglll (Bg), whereas the MT-I*
mRNA RT-PCR product is cut by EcoRV (RV). RT-
PCR products were radiolabeled by inclusion of a
32P-labeled primer in the PCR reaction. Restriction
products were separated by 12% nondenaturing
polyacrylamide gel electrophoresis and visualized
by autoradiography and quantitated by radioanaly-
sis ofthe gel.
Determination ofMT Levels in
Tissues
To determine whether MT accumulates to
higher levels in the testes and peri-implan-
tation uterus of transgenic mice, MT was
quantitated in heat-stable tissue extracts
using the cadmium-hemoglobin exchange
assay (24). Cadmium-binding was
increased significantly in all the major
organs examined from transgenic mice
compared with those from control mice
(Fig. 3), as expected from our previous
studies (23). In the transgenic testes, MT
levels were 5.2-fold higher than in control
mice, and in uterine implantation sites MT
levels were 8.7-fold higher on day 6 and
2.6-fold higher on day 8 than levels in con-
trol mice. As predicted by increases in MT-
I mRNA between day 6 and day 8, decid-
ual MT levels correspondingly increased
during this period in both transgenic and
control mice (Fig. 3). In general, the
increases in MT-I mRNA in the transgenic
compared to control mice (Fig. 1) are
accompanied by increases in heat-stable
cadmium-binding activity in these tissues.
Immunohistochemical Localization
ofMT
Expression of the mouse MTgenes is cell
specific in the pern-implantation uterus
(33,40) and in the testes (41). To deter-
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Figure 3. Determination of steady-state levels of MT in tissues oftransgenic and control female and male
mice. MT was determined by the cadmium-hemoglobin exchange assay (24) in heat-stable extracts pre-
pared from the tissues. Uterus, deciduum, liver, kidney, and pancreas were obtained from female trans-
genic and control mice. Day-4 uterus represents MT in the whole uterus, whereas day-6 uterus repre-
sents MT in the implantation sites, and day-8 deciduum represents MT in deciduum dissected free of the
myometrium. Testes were isolated from mature breeding males. Data represent the means ± SDs of at
leastthree independent assays oftissues pooled from three animals each. For each tissue the transgenic
MT level was significantly differentfrom control (p <0.001, Student's t-test).
mine whether the MT-I* gene is also
expressed in a cell-specific manner in these
transgenic mice, MT-I was immunolocal-
ized in the day-4 uterus, day-6 and day-8
deciduum, and in the testis (Fig. 4) using
an anti-MT-peptide antisera. Our studies
ofCD-1 mice demonstrated that abundant
MT-I mRNA is found in uterine luminal
and glandular epithelium on day 4 and in
the secondary decidual zone on days 6-8
(40). MT-I immunoreactivity was also
localized only to these locations in uterine
sections from control mice (Fig. 4A).
Specificity of the antisera was confirmed
using nonimmune sera (not shown) and by
antibody neutralization (Fig. 4) before
immunostaining. In uterine sections from
transgenic mice, MT immunostaining was
also restricted to the same cell types as in
nontransgenic mice (Fig. 4B), but the
immunostaining was notably more intense.
Sections from the testes ofcontrol mice
displayed only weak MT-I immunoreactiv-
ity confined to one or two Leydig cells per
field ofview (Fig. 5A). Using preabsorbed
antibody eliminated this staining (Fig. 5B).
In transgenic animals, MT immunoreactiv-
ity was also confined to Leydig cells (Fig.
5D, E), but the immunostaining was
intense and many Leydig cells were
immunopositive for MT. Interestingly, ele-
vated MT-I mRNA levels in the testes
reflect accumulation ofhigh levels ofthese
transcripts in the spermatogenic cells (41).
MT apparently does not accumulate in
germ cells, but does so at low levels in
Leydig cells in control mice and is elevated
in these cells in transgenic mice. The above
results establish that the MT-I* genes are
overexpressed, and MT accumulates to
higher levels in the proper cell types in the
testes and female reproductive tract in this
transgenic line ofmice.
Effects ofCadmium Injected on the
DayofBlastocyst Implantation
Previous studies have documented a
marked susceptibility of the blastocyst to
acute cadmium exposure both in vivo and
in vitro (11-13). We reported that subcuta-
neous injection of a sublethal dose ofcad-
mium (38 pmol/kg) on day 4 of pregnancy
resulted in loss of pregnancy, accompanied
by a loss in viability of blastocysts flushed
from the uterus on day 5 (11). However,
maternal effects of cadmium were also
noted in those -studies and were likely to
play a role in the loss of pregnancy. To
determine if cell-specific overexpression of
MT would protect against cadmium-
induced pregnancy failure, transgenic and
control mice were given a single subcuta-
neous injection ofcadmium on the morn-
ing ofday 4 of pregnancy, before blastocyst
implantation, and pregnancy was assessed
by gross dissection ofthe uterus on day 14
(Table 1). Mice used in these experiments
were divided into three groups based on
expression of MT: group 1 mice had nor-
mal maternal and embryonic MTgene
expression and consisted of nontransgenic
females (CD-1 or control) matedwith CD-
1 males. Group 2 mice had normal mater-
nal MTgene expression but overexpression
of embryonic MTand consisted of CD-I
females mated with heterozygous trans-
genic males (50% transgenic embryos).
Group 3 mice had maternal and embryonic
overexpression ofMTand consisted ofhet-
erozygous transgenic females mated with
CD-1 males (50% transgenic embryos).
In untreated mice, 90-100% of the
females that had a vaginal plug on day 1
were found to be pregnant at mid-gestation
(day 14), and there were no differences
among transgenic, control, and CD-1
females in the number ofimplantation sites
per uterus or the percentage of embryos
that had died and were resorbed by day 14
(Table 1). To examine the effects ofcadmi-
um on pregnancy, three doses (30, 40, and
45 pmol Cd/kg body weight) were admin-
istered on day 4 to mice in each of these
groups. Each of these doses of cadmium
reduced the pregnancy rate similarly in all
three groups of mice. An injection of 30
uimol Cd/kgslightly reduced the pregnancy
rate (to 80-90%) in each group, but had
no effect on the number of implantation
sites per uterus, the day-14 fetal weight, or
embryo resorption rate. In contrast, an
injection of 40 pmol Cd/kg resulted in a
sharp dedine in pregnancy rate (46-62%)
in all three groups (Table 1). In each exper-
iment the pregnancy rate was consistently
higher in mice with maternal and embry-
onic overexpression ofMT (group 3) than
in the other groups of mice. However,
there were no remarkable differences
between the three groups of mice with
regard to the effects of cadmium on preg-
nancy rate.
Under these experimental conditions,
40 pmol Cd/kg was at the low end of the
steep dose-response curve for lethality for
each of these groups of mice (Table 1). In
experiment 1, 40 ,umol Cd/kg did not kill
any of the mice examined. In contrast, in
experiment 2, 1 of24 transgenic mice died,
and 4 of 18 control mice died. An injection
of 45 pimol Cd/kg resulted in significant
lethality in all groups, but was below the
LD50. Surprisingly, there were no remark-
able differences in the dose-response curves
for cadmium lethality among these groups
of mice. It was noted that cadmium injec-
tion on day 4 resulted in an all-or-none
effect on pregnancy, which is consistent
Environmental Health Perspectives * Volume 104, Number 1, January 1996
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with maternal cadmium toxicity governing
pregnancy rate. In all three groups, mice
that escaped the effects of cadmium and
were pregnant on day 14 had a normal
number of implantation sites, and there
was no increase in resorption rate (Table 1)
Thus, embryonic overexpression of MT
afforded no selective advantage.
Effects ofCadmium on
Spermatogenesis
The rodent testis is highly sensitive to the
toxic effects of cadmium (9,10,42), and
necrosis occurs after the administration of
cadmium at levels well below those that
cause liver or kidney damage. Transgenic
or control male mice were injected with a
single subcutaneous dose of cadmium at
7.5 or 10 pmol/kg, and 24 hr or 48 hr later
the testes were recovered and examined his-
tologically (Fig. 6). The histology of the
testis 48 hr after an injection of 7.5 pmol
Cd/kg was unchanged in both transgenic
and control mice (Fig. 6A,B). However, 24
hr after an injection of 10 pmol Cd/kg,
alterations in the seminiferous epithelium
were apparent (Fig. 6C,D) and by 48 hr
extensive testicular necrosis, edema, and
sloughing of the seminiferous epithelium
had occurred in both transgenic and con-
trol mice (Fig. 6E,F). These results demon-
strate that overexpression ofMTaffords no
apparent protection against cadmium-
induced testicular necrosis.
Figure 4. Immunohistochemical localization of MT
in the peri-implantation uterus from transgenic
and control mice. Control (A) and (B) transgenic
mice were mated, and uteri were removed on day
4, or implantation sites were dissected from uteri
on days 6 and 8. See Methods for details. Dark
deposits show MTimmunostaining. Preabsorption
of the antisera with MT peptide eliminated
immunostaining (A, bottom right; B, top right). E,
epithelium (luminal and glandular); M, myometri-
um; PDZ, primary decidual zone; SDZ, secondary
decidual zone. (A) (top left) day-4 uterus, 28x; (top
right) day-4 uterus, 69x; (middle left) day-6
implantation site 28X; (middle right) day-6 implan-
tation site, 69x; (bottom left) day 8 implantation
site, 21x; (bottom right) day-6 preabsorbed antis-
era control, 28x. (B) (top left) day-4 uterus, and
(top right) preabsorbed antisera control, both 28x;
(bottom left) day 6 implantation site, 28X; (bottom
right) day-6 implantation site, 69x;(directly below)
day-8 implantation site, 25x.
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Figure 5. Immunohistochemical localization of MT in the testis of transgenic and control mice. Testes
were recovered from (A,B) control (-/-) and (C-E) transgenic (+/-) males. See Methods for details. Dark
deposits show MT immunostaining. Preabsorption ofthe antisera with peptide eliminated immunostaining
(B,C). SE, seminiferous epithelium; L, Leydig cell. Panels (A,B) 62x, (C,D) 69x, (E) 276x. Arrows indicate MT
immunostaining in Leydig cells. In panel A, control testes immunostaining was confined to one cell in this
field ofview, and the staining wasfaint, making it difficultto reproduce photographically.
Table 1. Effects of cadmium injection on day 4 of pregnancy in transgenic, control, and CD-1 micea
Parents n Pregnancy Embryos Embryos Embryo Parents Cd (total Lethality rate per resorbed weight
Female Male (pmol/kg) female) (%)b (%)C femaled (%) (g)
Experiment 1 CD-1 CD-1 30 10 0 80 10.9 ± 1.9 3.7 0.13
40 14 0 50 11.2±2.2 6.9
CD-1 Transgenic 30 9 0 89 12.0± 1.8 6.2 0.12
40 13 0 46 11.8±1.2 4.4
Transgenic CD-1 30 11 0 82 9.0±3.5 6.0 0.13
40 8 0 62 10.2 ± 1.8 7.8
Experiment2 CD-1 Transgenic 40 13 0 54 13.1 ±2.2
45 13 23 50 14.4 ± 1.3
Transgenic CD-1 40 24 4 60 10.3 ± 4.5
45 8 38 57 10.2±3.0
Control CD-1 40 18 22 57 12.0± 1.4
45 10 20 50 10.8±1.9
Untreated CD-1 CD-1 0 4 100 13.2 ± 1.5 3.8
Transgenic CD-1 0 20 90 10.5 ± 2.4 6.0
Control CD-1 0 11 - 100 12.4±1.8 5.3
aFemale and male mice of the indicated lines were mated, and on day 4 (day 1 = vaginal plug) females
were administered the indicated dosage of CdCI2 in a single 100 pl subcutaneous injection. On day 14 ani-
mals were sacrificed and pregnancy status was evaluated after gross dissection.
bDetermined as the number of animals that died between day 4 and day 14 of pregnancy, inclusive, divid-
ed bythe total number of animals injected with cadmium inthatgroup.
cDetermined asthe number ofday 14 pregnant animals divided bythetotal numberofmice alive on day 14.
dData representthe means ± SDs.
Discussion
The transgenic mice used in this study have
stable integration of56 copies of an MT-I*
transgene with 1.8 kb ofthe MT-I promot-
er and flanked by 10 kb ofDNA 5' ofthe
MT-II gene and 7 kb of DNA 3' of the
MT-Igene (2Z). This construct is expressed
in a manner that resembles the endogenous
MT-I gene (22,23,433. We extended those
studies to include the peri-implantation
uterus where the temporal as well as spatial
patterns of expression of the endogenous
MT-Igene (40) and the MT-I* transgene
were indistinguishable. This suggests that
the MT-I* transgene-LCR construct con-
tains all of the information necessary to
direct developmental expression ofthe MT-
Igene in the uterine epithelium and the
deciduum. Although the DNA regions
involved in this developmental regulation
are unknown, we recently reported that the
entire MTgene locus is activated in the
mouse deciduum (33). This is the only
known tissue in which each of the four
mouse MTgenes are activated, which sug-
gests that the chromatin domain structure
ofthe MTlocus may be particularly impor-
tant in regulatingexpression in these cells.
This transgenic mouse strain provided a
useful tool to examine the functional signif-
icance of MT in cadmium toxicity.
Specifically, effects of MT overexpression
on cadmium toxicity during early pregnan-
cy and on the testes were examined.
Surprisingly, these indicators did not reveal
a remarkable protective effect of overex-
pression of MT, although a slight protec-
tion from loss of pregnancy was noted.
Our previous studies of these transgenic
mice revealed that they are more resistant
to cadmium-induced hepatotoxicity and
acute lethality compared with control mice
(1-9), but the dose-response curves for cad-
mium-induced lethality revealed only a
subtle increase (1.2-fold) in cadmium
dosage resulted in equivalent lethality
between the transgenic and control mice.
Such subtle differences in dose response to
cadmium were not revealed in the limited
dose-response experiments here.
By comparison, cultured cells that over-
express MT, after transfection with an MT
expression vector, can resist 12- to 15-fold
higher concentrations of cadmium in the
culture medium than control cells (18),
and cultured cells selected for cadmium
resistance that overexpress MT can resist
up to 60-fold higher concentrations ofcad-
mium (44). Interestingly, primary hepato-
cytes from this transgenic strain that over-
expresses MT are about 7-fold more resis-
tant to cadmium toxicity in vitro. Thus,
large differences between transgenic and
control mice in their resistance to cadmium
toxicity were predicted based on studies of
cultured cells, but studies of these trans-
genic mice demonstrate that within the
physiological context ofthe animal, overex-
pression of MT affords little protection
from cadmium toxicity.
In contrast, studies of mice in which
the MT-Iand MT-IIgenes have been dis-
rupted suggest a significant increase in sen-
sitivity to cadmium-induced hepatotoxicity
and lethality (20,21). Although no detailed
dose-response curves for cadmium toxicity
have been reported, studies of these mice
reveal clear increases in cadmium toxicity.
Control mice can tolerate 14 daily injec-
tions of 10 pmol Cd/kg, whereas the
knockout mice succumb after 2-4 days,
depending on sex (21). Embryonic fibrob-
lasts from these knockout mice are also 2-
to 3-fold more sensitive to cadmium in
vitro than are control fibroblasts (45).
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Therefore, MT can serve a protective func-
tion against cadmium in vivo, but overex-
pression of MT in a proper cell-specific
manner does not significantly augment that
protective function.
It is perhaps surprising that overexpres-
sion ofMT at its normal sites ofsynthesis
in the mouse did not effectively protect
early pregnancy or spermatogenesis from
cadmium toxicity by scavenging cadmium
from the serum. After acute exposure to
cadmium, the liver can sequester up to
60% of the cadmium challenge (46,47),
and hepatotoxicity is closely associated
with cadmium-induced mortality (48,49).
MT in the transgenic liver was significandy
elevated, and the liver is considered respon-
sible for cadmium detoxification. Despite
these considerations, no protection was
afforded these reproductive processes, and
low levels of cadmium caused testicular
necrosis in both the control and transgenic
mice.
In the testes of nontransgenic animals,
MT immunostaining using an antipeptide
antisera was confined to a few Leydig cells.
In transgenic animals, MT immunostain-
ing was exclusively in Leydig cells, but was
much more intense. These results suggest
that the Leydig cell is the only cell that
accumulates immunodetectable MT in the
mouse testes and that levels ofMT are nor-
mally low in the control testes. Previous
studies have yielded conflicting results
regarding the immunolocalization of MT
in the rodent testes. MT has been shown to
be immunolocalized to Leydig cells in the
mouse testis (50), but in the rat testes MT
immunostaining in Sertoli cells and inter-
stitial cells has been reported (51), as has
localization in spermatogenic cells, but not
in interstitial cells (52). It is interesting that
MT immunoreactivity was not present in
mouse germ cells, as pachytene spermato-
cytes and round spermatids express high
levels of MT-I mRNA and can synthesize
MT (41). Pachytene spermatocytes and
round spermatids isolated from these trans-
genic mice also contained high levels of
MT-I mRNA, and the vast majority of it
was derived from the MT-I* transgene
(data not shown). The lack of MT
immunostaining in these germ cells is con-
Figure 6. Effects of cadmium injection on histology
of the testes from transgenic and control mice.
(A,C,E) Control (-I-) and (B,D,F)transgenic male lit-
termates were given a single injection of 7.5 pmol
Cd/kg (A,B) or 10 pmol Cd/kg (C-F), and the testes
were recovered 24 hr (C,D) or 48 hr (A,B,E,F) after
the injection. Testes were fixed in Bouin's solu-
tion, and paraffin sections were prepared and
stained with hematoxylin and eosin. SE, seminifer-
ous epithelium; L, Leydig cell; SSE, sloughing
seminiferous epithelium. (A-F) 39x.
sistent with the suggestion that MT accu-
mulation is controlled primarily by post-
transcriptional mechanisms in male germ
cells (41).
Some inbred strains of mice show
remarkable resistance to testicular necrosis
produced by lethal doses of cadmium
(53,54), and this is attributed to the auto-
somal recessive cdm gene (55). Although it
has been proposed that in the rat, testicular
susceptibility to cadmium is the result of
the low expression of MT genes (56,57),
the studies reported here suggest that the
cdm gene is a far more important genetic
determinant for testicular sensitivity to cad-
mium than is the level of testicular MT.
Overexpression ofMT in the testes was not
sufficient to protect from cadmium-
induced testicular damage. Leydig cells are
not required for the effects ofcadmium on
the testes (58), but elevation of MT in
Leydig cells present in the interstitium of
the testes might be expected to protect the
germ cells because the interstitium is the
major site ofcadmium accumulation in the
testes (59,60). Collectively, these studies
establish that MT in the interstitium is of
limited use in preventing testicular injury
after cadmium exposure.
Our earlier studies indicated that preg-
nancy failure after cadmium exposure on
day 4 may have resulted from a direct
embryotoxic effect on the blastocyst (11).
However, the results obtained here, using a
larger number of mice, strongly suggest
that effects ofcadmium on the mother play
the key role in the maintenance of preg-
nancy. Although transgenic blastocysts
from these mice display marked elevation
in MT (approximately 10-fold) compared
to control blastocysts and more resistant to
Cd toxicity in vitro (43), studies reported
here establish that transgenic embryos have
no selective advantage in vivo after mater-
nal exposure to cadmium under these
experimental conditions. Pregnancy failure
after cadmium exposure on day 4 may
result from effects on the uterus; for exam-
ple, on uterine receptivity for implantation.
We previously reported that cadmium can
cause a delay in the initiation ofimplanta-
tion (localized sites ofincreased uterine vas-
cular permeability) in mice (11). After
implantation, cadmium has restricted
access to the embryo, perhaps due to the
high levels ofMT expressed in the decidu-
um and visceral yolk sac (6,7,61). Despite
increased expression ofMT in these tissues,
the transgenic mice were not significantly
protected from cadmium toxicity during
theperi-implantation period.
Studies of cadmium toxicity in these
transgenic mice that overexpress MT are
consistent with the likelihood that cadmi-
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um exerts its lethal effects, in part, on cells
that do not overexpress MT. It has been
suggested that hepatic endothelial cells are
a target of cadmium toxicity and that this
may account for strain differences in sus-
ceptibility (62. Cadmium-induced testicu-
lar damage has also been suggested to result
from injury to the vasculature, which leads
to ischemia and death of seminiferous
epithelium (63-65). In that regard, the
process of blastocyst implantation involves
highly localized increases in vascular per-
meability at the sites of embryo implanta-
tion. Immunolocalization of MT in these
transgenic mice did not suggest enhanced
accumulation in endothelial cells of the
testes or uterus. The ovary and placenta are
also suceptible to cadmium toxicity (6),
but dosages of cadmium that disrupt the
testes had little effect on the establishment
and maintenance ofpregnancy.
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